GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) Stock Price & News

Q2 2027 earnings • released • EPS beat +20,18% • Revenue beat +9,66%

See results

GLAXO:NSE

GlaxoSmithKline Pharmaceuticals Ltd

2 499,00 ₹

-1,30%

(-32,80) 1D

5 նոյ, 15:30:01 GMT+5:30 · INR

All symbols

	Symbol	Price	Change	% Change

Generating top insights for GLAXO...

Open

2 549,80 ₹

High

2 573,40 ₹

Low

2 494,00 ₹

Mkt. cap

423,35 մլրդ

Avg. vol.

69,12 հզր

Volume

98,86 հզր

Dividend

2,28%

Quarterly dividend

14,25 ₹

Ex-dividend date

29 մյս, 2026 թ.

P/E ratio

39,63

52-wk high

3 120,70 ₹

52-wk low

2 088,10 ₹

EPS

63,05 ₹

Shares outstanding

169,41 մլն

No. of employees

3 հզր

Open

2 549,80 ₹

High

2 573,40 ₹

Low

2 494,00 ₹

Mkt. cap

423,35 մլրդ

Avg. vol.

69,12 հզր

Volume

98,86 հզր

Dividend

2,28%

Quarterly dividend

14,25 ₹

Ex-dividend date

29 մյս, 2026 թ.

P/E ratio

39,63

52-wk high

3 120,70 ₹

52-wk low

2 088,10 ₹

EPS

63,05 ₹

Shares outstanding

169,41 մլն

No. of employees

3 հզր

Related stocks

IPCALAB

IPCA Laboratories Ltd

Alkem Laboratories Ltd

5 190,00 ₹

-0,51%

News stories

From web sources and news partners

CNN

45 րոպե առաջ

Nasdaq plunges into correction territory as midterm results raise fresh questions about AI boom

marketscreener.com

44 րոպե առաջ

First Advantage Corporation (NasdaqGS:FA) acquired Data Diver Technologies, LLC for approximately $125 million.

StreetInsider

5 րոպե առաջ

SEGG Media Regains Nasdaq Compliance as Q2 Revenue Grows More Than 1,500%

Reuters

49 րոպե առաջ

Nasdaq set to confirm correction as AI spending worries mount

Profile

GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease, and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, and others. Wikipedia

About GlaxoSmithKline Pharmaceuticals Ltd

CEO-

Employees3,1 հզր

Founded13 նոյ, 1924 թ.

Headquarters-

Sector-

Industry-

Websiteindia-pharma.gsk.com

All values in INR	2025 թ. սեպ	2025 թ. դեկ	2026 թ. մրտ	2026 թ. հնս
Revenue	9,80 մլրդ	10,41 մլրդ	9,95 մլրդ	9,38 մլրդ
Cost of goods sold	3,56 մլրդ	3,64 մլրդ	3,69 մլրդ	3,28 մլրդ
Cost of revenue	3,56 մլրդ	3,64 մլրդ	3,69 մլրդ	3,28 մլրդ
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1,38 մլրդ	1,52 մլրդ	2,95 մլրդ	1,59 մլրդ
Operating expense	3,06 մլրդ	3,26 մլրդ	2,84 մլրդ	3,31 մլրդ
Total operating expenses	6,62 մլրդ	6,90 մլրդ	6,53 մլրդ	6,59 մլրդ
Operating income	3,18 մլրդ	3,51 մլրդ	3,43 մլրդ	2,80 մլրդ
Other non operating income	335,70 մլն	321,20 մլն	-1,09 մլրդ	437,60 մլն
EBT including unusual items	3,54 մլրդ	4,00 մլրդ	3,73 մլրդ	3,22 մլրդ
EBT excluding unusual items	3,51 մլրդ	3,82 մլրդ	2,94 մլրդ	3,22 մլրդ
Income tax expense	965,10 մլն	1,04 մլրդ	952,41 մլն	852,70 մլն
Effective tax rate	27,26%	26,08%	25,53%	26,44%
Other operating expenses	1,51 մլրդ	1,54 մլրդ	-236,82 մլն	1,56 մլրդ
Net income	2,57 մլրդ	2,96 մլրդ	2,78 մլրդ	2,37 մլրդ
Net profit margin	26,28%	28,39%	27,92%	25,27%
Earnings per share	-	-	-	14,00
Interest and investment income	-	-	657,30 մլն	-
Interest expense	-5,10 մլն	-11,90 մլն	-6,12 մլն	-9,70 մլն
Net interest expenses	-5,10 մլն	-11,90 մլն	651,18 մլն	-9,70 մլն
Depreciation and amortization charges	174,30 մլն	203,20 մլն	131,74 մլն	158,40 մլն
EBITDA	3,35 մլրդ	3,61 մլրդ	3,52 մլրդ	2,89 մլրդ
Gain or loss from assets sale	-	-	-	-

Finance

Ask anything